Quinine
Qualaquin (quinine) is a small molecule pharmaceutical. Quinine was first approved as Qualaquin on 2005-08-12. It is used to treat babesiosis, falciparum malaria, malaria, and muscle cramp in the USA. It is known to target potassium voltage-gated channel subfamily B member 2, equilibrative nucleoside transporter 4, and potassium channel subfamily K member 18.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Qualaquin (generic drugs available since 2012-09-28)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Quinine sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| QUALAQUIN | Sun Pharmaceutical Industries | N-021799 RX | 2005-08-12 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| qualaquin | New Drug Application | 2019-08-29 |
| quinine sulfate | NDA authorized generic | 2023-06-09 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| babesiosis | EFO_0007162 | D001404 | B60.0 |
| falciparum malaria | EFO_0007444 | D016778 | B50 |
| malaria | EFO_0001068 | D008288 | B54 |
| muscle cramp | HP_0003394 | D009120 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
M: Musculo-skeletal system drugs
— M09: Other drugs for disorders of the musculo-skeletal system in atc
— M09A: Other drugs for disorders of the musculo-skeletal system in atc
— M09AA: Quinine and derivatives for disorders of the musculo-skeletal system
— M09AA72: Quinine, combinations with psycholeptics
P: Antiparasitic products, insecticides and repellents
— P01: Antiprotozoals
— P01B: Antimalarials
— P01BC: Methanolquinolines, antimalarial
— P01BC01: Quinine
HCPCS
No data
Clinical
Clinical Trials
42 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malaria | D008288 | EFO_0001068 | B54 | — | 3 | 2 | 5 | 2 | 12 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | 1 | 3 | 5 |
| Anemia | D000740 | EFO_0004272 | D64.9 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Falciparum malaria | D016778 | EFO_0007444 | B50 | — | 2 | 2 | — | — | 4 |
| Covid-19 | D000086382 | U07.1 | — | 1 | 1 | — | — | 1 | |
| X-linked combined immunodeficiency diseases | D053632 | EFO_1001451 | — | 1 | 1 | — | — | 1 | |
| Cerebral malaria | D016779 | B50.0 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic pain | D059350 | HP_0012532 | — | 1 | — | — | — | 1 | |
| Compliance | D003187 | — | 1 | — | — | — | 1 | ||
| Sinusitis | D012852 | EFO_0007486 | J32 | 1 | 1 | — | — | — | 1 |
| Rhinitis | D012220 | EFO_0008521 | J31 | 1 | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Exploratory behavior | D005106 | EFO_0004316 | — | — | — | — | 1 | 1 | |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | QUININE |
| INN | — |
| Description | Quinine is a cinchona alkaloid that is cinchonidine in which the hydrogen at the 6-position of the quinoline ring is substituted by methoxy. It has a role as an antimalarial, a muscle relaxant and a non-narcotic analgesic. It is a conjugate base of a quinine(1+). It derives from a hydride of an (8S)-cinchonan. |
| Classification | Small molecule |
| Drug class | anti-inflammatory agents (salicylic acid derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12 |
Target
Agency Approved
No data
Alternate
KCNB2
KCNB2
SLC29A4
SLC29A4
KCNK18
KCNK18
Organism
Homo sapiens
Gene name
KCNB2
Gene synonyms
NCBI Gene ID
Protein name
potassium voltage-gated channel subfamily B member 2
Protein synonyms
delayed rectifier potassium channel protein, potassium channel Kv2.2, potassium channel, voltage gated Shab related subfamily B, member 2, potassium voltage-gated channel, Shab-related subfamily, member 2, Voltage-gated potassium channel subunit Kv2.2
Uniprot ID
Mouse ortholog
Kcnb2 (98741)
potassium voltage-gated channel subfamily B member 2 (E9Q5T7)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 42,220 documents
View more details
Safety
Black-box Warning
Black-box warning for: Qualaquin, Quinine sulfate
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
29 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more